EU/3/04/245

Table of contents

About

On 16 November 2004, orphan designation (EU/3/04/245) was granted by the European Commission to PharmaMar SA Sociedad Unipersonal, Spain, for aplidine for the treatment of multiple myeloma.

Key facts

Active substance
Aplidine
Disease / condition
Treatment of multiple myeloma
Date of decision
16/11/2004
Outcome
Positive
Orphan decision number
EU/3/04/245

Sponsor's contact details

Phama Mar S.A. Sociedad Unipersonal
Polígono Industrial La Mina
Avda de los Reyes 1
E-28770 Colmenar Viejo
Madrid
Spain
Telephone: +34 91 84 66 000
Telefax: +34 91 84 66 001
E-mail: pharmamar@pharmamar.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Austrian Myeloma Association
    Bürglsteinstr. 21-10
    5020 Salzburg
    Austria
  • International Myeloma Foundation (UK)
    Lower Ground Floor
    37 York Place
    Edinburgh
    Scotland
    EH1 3HP
    United Kingdom
    Myeloma Infoline: 0800 980 3332 (freephone for UK)
    Telephone: +44 13 15 57 33 32 (Administration)
    Telefax: +44 13 15 56 97 20
    E-mail: TheIMF@myeloma.org.uk
  • Danish Myeloma Association
    (Dansk Myelomatose Forening)
    v/ Peter Randløv
    Klosterbakken 40
    DK-3500 Værløse
    Denmark
    Telephone: +45 44 48 41 27
    E-mail: randlov@post9.tele.dk

How useful was this page?

Add your rating